Haloperidol Blood Levels and Clinical Effects

Jan Volavka, Thomas Cooper, Pal Czobor, Istvan Bitter, Morris Meisner, Eugene Laska, Pedro Gastanaga, Menahem Krakowski, Martha Crowner, Richard Douyon

Research output: Contribution to journalArticle

99 Citations (Scopus)


This study explored the relationships between plasma levels and the clinical effects of haloperidol in 176 acutely exacerbated schizophrenic or schizoaffective patients. After a single-blind placebo period of 1 week (period 1), they entered the double-blind period 2 randomly assigned to one of three plasma levels of haloperidol: low (2 to 13 ng/mL), medium (13.1 to 24 ng/mL), or high (24.1 to 35 ng/mL). Patients whose conditions did not improve in period 2 continued on one of the three haloperidol levels (period 3). Periods 2 and 3 lasted 6 weeks each. Only minor differences in clinical responses were noted among the three levels of haloperidol. These results imply that low or moderate doses of neuroleptics are appropriate for many acutely psychotic patients.

Original languageEnglish
Pages (from-to)354-361
Number of pages8
JournalArchives of General Psychiatry
Issue number5
Publication statusPublished - May 1992

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Haloperidol Blood Levels and Clinical Effects'. Together they form a unique fingerprint.

  • Cite this

    Volavka, J., Cooper, T., Czobor, P., Bitter, I., Meisner, M., Laska, E., Gastanaga, P., Krakowski, M., Crowner, M., & Douyon, R. (1992). Haloperidol Blood Levels and Clinical Effects. Archives of General Psychiatry, 49(5), 354-361. https://doi.org/10.1001/archpsyc.1992.01820050018002